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Editorial on the Research Topic
Monitoring Pathophysiology in the Injured Brain
iNtrodUCtioN
Brain injuries can be caused by, for instance, spontaneous hemorrhages, thromboembolic incidents 
or traumatic events, and are considerable sources of morbidity and mortality (1). Brain injuries 
commonly result in immense socioeconomic consequences due to the acute as well as persisting 
neurological deficits (2). To date, there are currently few pharmacological therapies of proven clini-
cal benefit targeting the underlying pathophysiology occurring in the aftermath of subarachnoid 
hemorrhage (SAH) (3), stroke (4), and traumatic brain injury (TBI) (5). Although these brain 
injuries are exceedingly heterogeneous, some common pathophysiological phases may be identified. 
At disease onset, the primary ictus may cause initial neuronal, glial, and vascular injury, which is 
then followed by complex pathophysiological responses. The initial tissue injury is then exacerbated 
by secondary insults, occurring in the vulnerable brain during the first post-injury period (6). The 
secondary injury cascades include among others neuroinflammation, energy failure, hypoxia, and 
inadequate cerebral perfusion (7). By monitoring multiple intracerebral as well as systemic param-
eters across a range of modalities, the time course of these detrimental secondary injury cascades can 
be ascertained. Importantly, knowledge acquired from monitoring and investigation of these injury 
processes is expected to facilitate the future development of novel treatment strategies. Recently, 
improved intracranial monitoring was stressed as one of the key areas of research by a commissioned 
article devoted to TBI in a Lancet Neurology editorial (8).
In this Research Topic, a number of authors from several key centers of excellence worldwide 
have shared their knowledge on the monitoring of acute brain injuries. These contributions provide 
updated knowledge of the pathophysiology of TBI and other acute brain injuries, as well as of refin-
ing patient management strategies. The overall goal of improving patient outcomes by the detection 
of deleterious secondary injury processes occurring in the injured brain.
NEUroiMaGiNG
•	 Stovell et al. reviewed the monitoring of brain metabolism using magnetic resonance spectroscopy 
(MRS) in acute TBI. While this technique is still in its infancy, it holds much promise as increasing 
evidence suggests that deranged metabolism is a major exacerbating factor following brain injury, 
especially in relation to mitochondrial dysfunction. The MRS technique shows potential for the 
evaluation of specific brain regions where tissue fate may be analyzed granularly in both acute and 
chronic phases of brain injury.
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•	 Rostami et al. evaluated the correlation between cerebral blood 
flow and metabolism in patients following SAH monitored 
using Xenon-CT in combination with cerebral microdialysis 
(CMD). They observed that reduced global blood flow the 
first 3 days post-SAH was significantly associated with brain 
metabolism monitored using CMD, specifically high levels of 
lactate indicating anaerobic metabolism. These results suggest 
that monitoring of cerebral blood flow and brain neurochem-
istry could aid physicians and guide treatments, such as 
optimizing cerebral perfusion pressure (CPP) and adjusting 
oxygen and glucose substrate levels in SAH patients.
CoaGUlatioN
•	 Lindblad et  al. evaluated multiple electrode aggregometry 
(Multiplate®) used to assess platelet functions in NICU-
treated TBI patients. Although platelet count may be normal, 
several studies have shown that they do not function properly 
following TBI. Thus, the primary hemostasis may be altered, 
specifically by an impaired response of the arachidonic acid 
(ASPI) receptor. The authors could show that 65% of the 
included TBI patients had abnormally low ASPI values. This 
was associated with a more unfavorable outcome, although 
interestingly not with hemorrhagic progression. These results 
highlight the need for future research and validated methods 
of platelet assessment for patients not on platelet anti-aggrega-
tion therapies.
CliNiCal iNVEStiGatioNS
•	 Marklund evaluated the current role of the neurological 
wake-up test (NWT) in neurocritical care monitoring, 
reviewing the available literature. While intracranial pressure 
(ICP) and CPP monitoring as well as serum markers indicate 
that the NWT could induce a mild stress response including 
increased ICP and the release of stress-related hormones, the 
consequences of these are not fully understood. While quali-
tative prospective studies concerning its safety are lacking, the 
NWT remains an important monitoring tool in selected TBI 
and SAH patients, preferably in combination with multimodal 
monitoring.
CErEBral MiCrodialYSiS
•	 Carteron et al. report on how CMD has allowed them to indi-
vidualize neurocritical care therapy in TBI and SAH patients. 
Specifically, CMD may help guide optimization of CPP, blood 
transfusions, glucose infusions, and brain tissue oxygenation 
targets. Newer markers include electrolytes, markers of 
oxidative stress, or endothelial proteins, which may also be 
measured by CMD in order to better predict outcome or guide 
treatment.
•	 Helbok et  al. conducted a systematic review on the clinical 
use of CMD in patients with aneurysmal SAH, focusing on 
secondary brain injury and clinical outcome. They found that 
the metabolic changes detected by CMD were associated with 
early and delayed secondary brain injuries and suggested that 
CMD be used in conjuncture with other monitoring modal-
ities. In summary, while CMD in SAH is less studied than 
in TBI, it is an emerging area that might establish itself as a 
future standard monitor of SAH patients, awaiting additional 
investigations and multi-center trials.
BioMarKEr MoNitoriNG
•	 Ercole et al. review and summarize several different technol-
ogies to monitor molecular signals in TBI. Mass spectroscopy 
as well as optical spectroscopy also hold a potential to unravel 
the in vivo molecular signatures in TBI patients. Altogether, by 
introducing an “-omics” approach in TBI, it will be possible 
to gain further understanding of the systems biology involved.
•	 Posti et al. reviewed the field of metabolomic monitoring as a 
diagnostic tool in severe TBI, by investigating different metab-
olites (fatty acids, amino acids, as well as sugar derivates), 
and how they are associated with injury severity and clinical 
outcome. This is a promising field although larger prospective 
trials are necessary to establish better thresholds and specific 
metabolic patterns associated with brain injury and patient 
outcome.
•	 Thelin et al. analyzed the current literature, focusing on some 
of the most commonly studied biomarkers including S100B, 
neuron-specific enolase (NSE), glial fibrillary acidic protein 
(GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), 
and neurofilament light (NF-L) in order to review serum level 
dynamics of these proteins following TBI. In aggregate, shorter 
half-lives were seen for S100B and UCH-L1 in contrast to 
NSE, GFAP, and especially NF-L that exhibit increased levels 
for prolonged periods of time post-injury. These differences 
should be taken into account when assessing the capability of 
these biomarkers to predict outcome and monitor secondary 
pathologies in TBI patients.
•	 Tsitsopoulos et al. reviewed possibilities for short- and long-
term monitoring of axonal injury in TBI. Biomarkers, specifi-
cally NF-L, is mentioned as a potential diagnostic candidate, as 
it has been found enriched in myelinated axons and seen to be 
elevated in serum in patients with radiologically verified DAI. 
Novel MRI tools are increasingly used for the detection and 
progress of axonal injury.
NEUroiNFlaMMatioN
•	 Zeiler et al. reviewed the literature on CMD and CSF cytokines 
in both TBI and SAH patients. They could conclude that there 
is an association with elevated levels of certain cytokines, 
among others, interleukin-6 and tumor necrosis factor alpha, 
and long-term functional outcome. In summary, cytokines 
as mediators of inflammatory activity can be monitored in 
the extracellular fluid by CMD and in CSF and appear to be 
associated with secondary injury pathophysiology and clinical 
outcome in both TBI and SAH.
•	 Thelin et  al. reviewed several modalities that are used to 
monitor the neuroinflammatory response following acute 
brain injury, focusing on TBI and SAH. In summary, the 
authors suggest a multimodal monitoring approach in order 
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to improve the understanding of the neuroinflammatory 
response following acute brain injury to determine its role for 
tissue as well as patient outcome.
•	 Vink et al. summarize the role of Substance P in the secondary 
pathophysiology of TBI, reviewing its role in the neurogenic 
inflammation and association to ICP increases as observed 
in several of their studies. In summary, the role of substance 
P in neurogenic inflammation following TBI is increasingly 
understood and opens up potential future therapeutic targets 
for patients suffering from acute brain injury.
trEatMENt StratEGiES
•	 Zoerle et al. address in their review how to rethink the con-
cept of neuroprotection. They suggest that different aspects 
of TBI care need to be refined and related to TBI pathophys-
iology, thus requiring individualized care in part guided by 
advanced monitoring approaches. These monitoring tools 
could prompt the clinicians to earlier detection of signs that 
may need treatment. By using these improved neurocritical 
care interventions, more adequate neuroprotection might be 
achieved.
MoNitoriNG StratEGiES
•	 Nordström et  al. have written a summary on aspects of the 
physiological and biochemical foundations of NCC treatment 
strategies. Here, they address the basic concepts of NCC with 
focus on the key aspects that form the base for the Lund con-
cept, including intracapillary hydrostatic pressure modulation, 
fluid therapies, and the implementation of brain tissue oxygen- 
and CMD monitoring.
•	 Grände critically evaluates the Lund concept, 25 years after its 
introduction. He focuses his review on temperature, ventila-
tion, nutrition, osmotherapy, decompressive craniectomy, and 
sedation management. Following the introduction of more 
advanced monitoring techniques such as CMD, brain tissue 
oxygen monitoring, and other ICP- and CPP-guiding proto-
cols, many current NCC strategies and targets have gradually 
approached several of those comprising the Lund concept.
•	 Figaji reviewed how treatment and monitoring of TBI and 
spinal cord injury differs between adults and children. As 
especially younger children have different anatomy and 
physiology than adults, there are several aspects, which need 
to be considered by the treating physician. One of the main 
findings of this literature review is the lack of suitable studies 
focusing primarily on the pediatric CNS following acute brain 
and spinal injury. This lack of knowledge could lead to adult 
thresholds and ranges for intracranial monitoring parameters 
being used in many pediatric situations, which might be inap-
propriate or even harmful to this patient population.
CoNClUSioN
In this research topic, many aspects of the current knowledge 
and possible future direction of multimodal monitoring in TBI 
patients are reviewed. Commonly, only limited aspects of the 
underlying pathophysiology in acute brain injury can and are 
monitored in the clinical setting. Introducing additional moni-
toring modalities including parameters such as inflammation 
markers, multiple metabolites, and a more granular evaluation of 
structural injuries, a more comprehensive understanding of the 
evolution of TBI pathology and ongoing secondary injury pro-
cesses may emerge in the near future. This will require continued 
large research efforts, but is expected to facilitate development of 
novel therapeutic options, personalized medicine, and treatment 
strategies for patients suffering from acute brain injury.
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